1. Home
  2. TRP vs ALNY Comparison

TRP vs ALNY Comparison

Compare TRP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TC Energy Corporation

TRP

TC Energy Corporation

N/A

Current Price

$63.62

Market Cap

56.9B

Sector

N/A

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$322.59

Market Cap

52.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRP
ALNY
Founded
1951
2002
Country
Canada
United States
Employees
N/A
115
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9B
52.9B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
TRP
ALNY
Price
$63.62
$322.59
Analyst Decision
Hold
Strong Buy
Analyst Count
3
28
Target Price
$76.67
$472.78
AVG Volume (30 Days)
2.2M
1.1M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
3.84%
N/A
EPS Growth
N/A
206.88
EPS
N/A
2.33
Revenue
N/A
$1,037,418,000.00
Revenue This Year
$7.31
$52.78
Revenue Next Year
$2.16
$31.86
P/E Ratio
$25.89
$137.47
Revenue Growth
N/A
22.88
52 Week Low
$45.26
$205.87
52 Week High
$65.57
$495.55

Technical Indicators

Market Signals
Indicator
TRP
ALNY
Relative Strength Index (RSI) 60.99 41.52
Support Level $53.16 $309.57
Resistance Level $63.94 $333.70
Average True Range (ATR) 1.11 9.92
MACD -0.26 1.26
Stochastic Oscillator 54.13 28.53

Price Performance

Historical Comparison
TRP
ALNY

About TRP TC Energy Corporation

TC Energy operates natural gas transmission assets across North America. Segments are determined by country of operation, but both Canadian and US operations are interconnected. Mexican operations are disconnected from the US and only have one customer, the state utility CFE. They also operate power generation assets, with the largest being the Bruce Power nuclear plant.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: